Skip to content
Company Analysis

Organon & Co. OGN

A comprehensive view of key metrics, scores, and financial health for Organon & Co.

Overview of Organon & Co.

OGN NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mid Cap
Organon & Co. (OGN), is a Mid Cap company, in the Drug Manufacturers - General industry, last closed at $13.82, about 267.1% undervalued vs fair value, +106.0% 1Y return, ranked 1086/1145 in sector.
Metrics P/E 10.0× Rev Growth -2.9% ROE 30.6% Gross Margin 53.3% Div Yield 4.72%
USD 13.82
-0.14%
(Delayed)
• Vol 90d: 2.9%
52-Week Range
Market Cap
$3.63B
Enterprise Value
$11.05B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.organon.com
HQ Jersey City, NJ
Employees 10,000
Fiscal year Dec 31

Next Events

Dividend Nov 9

Fair Value Snapshot

Bear Base Bull
$46
$51
$56
Current: $13.82 +267% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$6.2B
-2.9%%
Gross Profit
$3.3B
-10.8%%
R&D Expense
$366.0M
-22%%
Operating Income (EBIT)
$929.0M
-30%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
75.3%
Fair

Moderate cash conversion - some working capital drag

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$319.0M
54.3% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
1/5
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Organon & Co.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
40
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.78), demonstrating pricing resilience across cycles.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.94), suggesting sticky customer base.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.16), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.11), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
53
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing OGN's balance between Growth (19.9%), Profitability (53.7%), and Safety (26.4%). Growth 20% Safety 26% Profitability 54%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

23th percentile vs peers
24
Key Signals
Revenue CAGR 3Y 0.2% 36p Rev Growth YoY -2.9% 29p EPS Growth YoY -78.5% 13p TSR -49.7% 19p EPS CAGR 3Y -41.6% 8p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Consistently strong margins across 4 metrics
Risks
  • EPS Growth YoY in bottom 20% of peers (-78.5%)

Profitability

64th percentile vs peers
64
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

31th percentile vs peers
32
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Organon & Co..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$50.73
- - -
+267.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000